David A. Siegel Uro Gen Pharma Ltd. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 24,500 shares of URGN stock, worth $257,740. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,500

Previous 24,900 1.61%

Holding current value

$257,740

Previous $417,000 25.42%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$12.7 - $17.92 $5,080 - $7,168	-400 Reduced 1.61%	24,500 $311,000
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $77,592 - $117,120	6,100 Added 32.45%	24,900 $417,000
Q1 2024 May 15, 2024	BUY	$13.81 - $19.33 $6,905 - $9,665	500 Added 2.73%	18,800 $282,000
Q4 2023 Feb 14, 2024	SELL	$10.87 - $15.93 $6,521 - $9,558	-600 Reduced 3.17%	18,300 $274,000
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $167,076 - $427,896	18,900 New	18,900 $264,000
Q2 2019 Aug 14, 2019	SELL	$32.75 - $40.35 $288,200 - $355,080	-8,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$35.47 - $54.55 $63,846 - $98,190	1,800 Added 25.71%	8,800 $325,000
Q4 2018 Feb 14, 2019	SELL	$38.35 - $50.39 $42,185 - $55,429	-1,100 Reduced 13.58%	7,000 $301,000
Q3 2018 Nov 14, 2018	SELL	$41.65 - $51.7 $87,465 - $108,570	-2,100 Reduced 20.59%	8,100 $383,000
Q2 2018 Aug 14, 2018	BUY	$48.35 - $65.33 $493,170 - $666,366	10,200 New	10,200 $508,000

Others Institutions Holding URGN

# of Institutions

130

Shares Held

35.9M

Call Options Held

22K

Put Options Held

93.8K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $239M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account